New shot for tough lymphomas shows early promise but trial halted
NCT ID NCT06018129
First seen Nov 01, 2025 · Last updated Jun 21, 2026 · Updated 38 times
Summary
This early-stage trial tested a new drug called GEN3017 in 9 people with CD30-positive lymphomas (Hodgkin and non-Hodgkin) that had returned or stopped responding to standard treatments. The drug was given as a shot under the skin. The main goals were to check safety and find the right dose. The trial was terminated early, so we have limited information on how well it works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Helford Clinical Research Hospital
Duarte, California, 91010, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Peter MacCallum Cancer Institute trading as Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GEN3017 (a bispecific antibody that targets CD3 and CD30, given as a shot under the skin)
What this could lead to
If successful, this could point toward a new treatment option for people with certain lymphomas that have not responded to other therapies.
What could go wrong
This was a very early (phase 1/2a) trial that was terminated after only 9 participants, so results are limited. The drug may cause serious side effects like cytokine release syndrome or nerve toxicity.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.